US Patent

US7488827 — Muscarinic acetylcholine receptor antagonists

Composition of Matter · Assigned to Glaxo Group Ltd · Expires 2027-12-18 · 2y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects muscarinic acetylcholine receptor antagonists and methods of using them.

USPTO Abstract

Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.

Drugs covered by this patent

Patent Metadata

Patent number
US7488827
Jurisdiction
US
Classification
Composition of Matter
Expires
2027-12-18
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Glaxo Group Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.